[go: up one dir, main page]

MX2018009524A - TNFR FUSION POLYPEPTIDE COMPOSITIONS: ARGININE-FREE FC AND METHODS OF USE. - Google Patents

TNFR FUSION POLYPEPTIDE COMPOSITIONS: ARGININE-FREE FC AND METHODS OF USE.

Info

Publication number
MX2018009524A
MX2018009524A MX2018009524A MX2018009524A MX2018009524A MX 2018009524 A MX2018009524 A MX 2018009524A MX 2018009524 A MX2018009524 A MX 2018009524A MX 2018009524 A MX2018009524 A MX 2018009524A MX 2018009524 A MX2018009524 A MX 2018009524A
Authority
MX
Mexico
Prior art keywords
methods
free
arginine
fusion polypeptide
polypeptide compositions
Prior art date
Application number
MX2018009524A
Other languages
Spanish (es)
Other versions
MX421100B (en
Inventor
Ke Gong
Kevin Maloney
Roy Alston
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2018009524A publication Critical patent/MX2018009524A/en
Publication of MX421100B publication Critical patent/MX421100B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Aspectos de la invención que están dirigidos a composiciones que contienen polipéptidos exentos de arginina, y a los métodos para tratar trastornos asociados con la inflamación o la respuesta inmune; en particular, el polipéptido es etanercept.Aspects of the invention which are directed to compositions containing arginine-free polypeptides, and methods of treating disorders associated with inflammation or immune response; in particular, the polypeptide is etanercept.

MX2018009524A 2011-07-01 2012-06-29 TNFR:FC FUSION POLYPEPTIDE COMPOSITIONS ARGININE-FREE AND METHODS OF USE MX421100B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161504110P 2011-07-01 2011-07-01
PCT/US2012/044988 WO2013006454A1 (en) 2011-07-01 2012-06-29 Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use

Publications (2)

Publication Number Publication Date
MX2018009524A true MX2018009524A (en) 2021-11-16
MX421100B MX421100B (en) 2025-02-10

Family

ID=46579322

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014000093A MX358137B (en) 2011-07-01 2012-06-29 COMPOSITIONS OF THE TNFR FUSION POLYPEPTIDE: FC ARGININE EXEMPTS AND METHODS OF USE.
MX2018009524A MX421100B (en) 2011-07-01 2012-06-29 TNFR:FC FUSION POLYPEPTIDE COMPOSITIONS ARGININE-FREE AND METHODS OF USE

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014000093A MX358137B (en) 2011-07-01 2012-06-29 COMPOSITIONS OF THE TNFR FUSION POLYPEPTIDE: FC ARGININE EXEMPTS AND METHODS OF USE.

Country Status (13)

Country Link
US (2) US10995130B2 (en)
EP (1) EP2726090B1 (en)
JP (2) JP6463968B2 (en)
KR (1) KR102061355B1 (en)
CN (2) CN103930124B (en)
AU (2) AU2012279205B2 (en)
BR (1) BR112013033671B1 (en)
CA (1) CA2840711C (en)
DK (1) DK2726090T3 (en)
EA (1) EA026226B1 (en)
MX (2) MX358137B (en)
WO (1) WO2013006454A1 (en)
ZA (1) ZA201400490B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
SG10201811256QA (en) 2011-06-28 2019-01-30 Inhibrx Lp Serpin fusion polypeptides and methods of use thereof
AU2012279205B2 (en) 2011-07-01 2017-08-31 Biogen Ma Inc. Arginine - free TNFR : Fc- fusion polypeptide compositions and methods of use
TWI595883B (en) * 2011-10-18 2017-08-21 柯赫勒斯生物科學有限公司 Enesitol formulation stabilized with xylitol
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
WO2014011672A1 (en) * 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
PE20150964A1 (en) 2012-09-07 2015-07-25 Coherus Biosciences Inc STABLE AQUEOUS FORMULATIONS OF ADALIMUMAB
BR112015005161A2 (en) 2012-09-11 2017-07-04 Coherus Biosciences Inc correctly folded etanercept in high purity and excellent yield
EP2926834A4 (en) 2012-11-27 2016-04-20 Alteogen Inc Composition for stabilizing fusion protein in which protein and fc domain are fused
MX2015015051A (en) * 2013-05-02 2016-06-10 Mabxience S A Alternative formulations for tnfr: fc fusion polypeptides.
WO2015056613A1 (en) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Stabilized polypeptide aqueous preparation
ES2572919T3 (en) 2014-05-23 2016-06-03 Ares Trading S.A. Liquid pharmaceutical composition
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
HUE029849T2 (en) 2014-05-23 2017-04-28 Ares Trading Sa Liquid pharmaceutical composition
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HK1244685A1 (en) 2014-12-22 2018-08-17 阿雷斯贸易股份有限公司 Liquid pharmaceutical composition
KR20170138426A (en) * 2015-03-13 2017-12-15 삼성바이오에피스 주식회사 Anti-TNF-alpha polypeptide compositions and uses thereof
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
KR102446838B1 (en) 2016-10-21 2022-09-26 암젠 인크 Pharmaceutical formulations and methods for their preparation
EP3533441A4 (en) * 2016-10-28 2019-12-04 Celltrion Inc. STABLE PHARMACEUTICAL FORMULATION
CA3042126A1 (en) 2018-05-03 2019-11-03 Michael A. Portman Methods of treating kawasaki disease
CN111228225B (en) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 Recombinant human tumor necrosis factor receptor-Fc fusion protein freeze-dried preparation
GB201901547D0 (en) 2019-02-05 2019-03-27 Arecor Ltd Stabilized Fc Fusion protein solutions
CN118510549A (en) * 2021-09-22 2024-08-16 圣诺制药公司 Nanoparticle pharmaceutical compositions with reduced nanoparticle size and improved polydispersity index

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2366785C (en) 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
AU2003211991B2 (en) * 2002-02-14 2008-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution formulations
EP3210624A1 (en) * 2002-02-27 2017-08-30 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
PT1478394E (en) * 2002-02-27 2008-10-08 Immunex Corp Stabilized tnfr-fc composition comprising arginine
KR100471843B1 (en) 2002-06-11 2005-03-08 현대자동차주식회사 Mounting structure of out side weather strip in automobile
EP1592440A4 (en) * 2003-02-10 2007-07-11 Elan Pharm Inc Immunoglobulin formulation and method of preparation thereof
US8937045B2 (en) 2003-02-28 2015-01-20 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding proteins
NZ545221A (en) * 2003-08-01 2009-09-25 Amgen Inc Crystalline tumor necrosis factor receptor 2 polypeptides
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
US20110046059A1 (en) * 2005-09-06 2011-02-24 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
JP2009534390A (en) * 2006-04-21 2009-09-24 アムジェン インコーポレイテッド Buffers for biopharmaceutical formulations
WO2008051363A2 (en) 2006-10-20 2008-05-02 Amgen Inc. Stable polypeptide formulations
JP2010523695A (en) * 2007-04-11 2010-07-15 アルコン リサーチ， リミテッド Use of inhibitors of TNFα and antihistamines to treat allergic rhinitis and allergic conjunctivitis
CA2707483A1 (en) 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
EP2598167B1 (en) * 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
AU2012279205B2 (en) 2011-07-01 2017-08-31 Biogen Ma Inc. Arginine - free TNFR : Fc- fusion polypeptide compositions and methods of use

Also Published As

Publication number Publication date
AU2017265026B2 (en) 2019-10-24
CA2840711C (en) 2023-10-17
ZA201400490B (en) 2017-09-27
CN113244374A (en) 2021-08-13
WO2013006454A1 (en) 2013-01-10
US20140255400A1 (en) 2014-09-11
MX358137B (en) 2018-08-06
EP2726090A1 (en) 2014-05-07
EA026226B1 (en) 2017-03-31
US20210309719A1 (en) 2021-10-07
US10995130B2 (en) 2021-05-04
BR112013033671A2 (en) 2017-01-24
MX2014000093A (en) 2014-11-12
JP2014518276A (en) 2014-07-28
NZ620160A (en) 2016-07-29
AU2012279205A1 (en) 2014-02-06
JP2017186349A (en) 2017-10-12
CN103930124B (en) 2021-05-11
MX421100B (en) 2025-02-10
CN103930124A (en) 2014-07-16
US11834491B2 (en) 2023-12-05
AU2012279205B2 (en) 2017-08-31
CA2840711A1 (en) 2013-01-10
DK2726090T3 (en) 2020-01-20
BR112013033671B1 (en) 2022-10-18
AU2017265026A1 (en) 2017-12-07
EA201490195A1 (en) 2014-04-30
KR102061355B1 (en) 2019-12-31
KR20140056218A (en) 2014-05-09
JP6463968B2 (en) 2019-02-06
EP2726090B1 (en) 2020-01-01

Similar Documents

Publication Publication Date Title
MX2018009524A (en) TNFR FUSION POLYPEPTIDE COMPOSITIONS: ARGININE-FREE FC AND METHODS OF USE.
CL2024003234A1 (en) Modified polypeptides and their uses.
MX2023008559A (en) Il15/il15rî± heterodimeric fc-fusion proteins.
AR118560A2 (en) METHODS AND COMPOSITIONS INCLUDING PURIFIED RECOMBINANT POLYPEPTIDES
MX2023013729A (en) CHIMERIC FLT3 RECEPTORS AND METHODS OF USE THEREOF.
AR098465A1 (en) ANTI-a-SINUCLEINE ANTIBODIES AND METHODS OF USE
CO2018002450A2 (en) Gitrl fusion proteins and uses thereof
CO2017000507A2 (en) Chimeric bcma antigen receptor
GT201400147A (en) PYRIMIDINES AND FUSIONATED TRIAZINS REPLACED AND ITS USE
EA201791253A1 (en) ANTIBODIES TO MYOSTATIN, POLYPEPTIDES, CONTAINING OPTIONS OF FC-REGIONS, AND METHODS OF THEIR APPLICATION
CO2017000506A2 (en) Chimeric cll-1 antigen receptor
MX2016007219A (en) Novel methods.
CL2015002654A1 (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
EA201891420A1 (en) ANTIBODIES TO MYOSTATIN, POLYPEPTIDES, CONTAINING OPTIONS OF FC-REGIONS, AND METHODS OF THEIR APPLICATION
UY37456A (en) IMMUNOGLOBULINAS AND ITS USES
UY36021A (en) FC MULTIMÈRIC PROTEINS
MX376324B (en) DESMOGELIN-BINDING PROTEINS 2 (DSG2) AND THEIR USES.
EA201590993A1 (en) HETERODIMERNY IMMUNOHLOBULINS
MX2017002205A (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment.
EA202090632A1 (en) METHODS AND COMPOSITIONS FOR TREATING DISORDERS WITH THE USE OF FALLISTATIN POLYPEPTIDES
EA202091342A2 (en) INTERLEUKIN-2 FUSION PROTEIN / INTERLEUKIN-2 ALPHA RECEPTOR AND METHODS OF USE
BR112014026740A8 (en) antibody, composition, method of providing an antibody with enhanced adcc, and, use of an antibody
NI201500117A (en) FUSIONED PYRIMIDINES REPLACED WITH TRIFLUOROMETHYL AND ITS USES.
EA201391773A1 (en) CELLS-PRECURSORS OF THE MESODERMAL LINE
MX2016011561A (en) Insulin-like growth factor 1 receptor -specific antibodies and uses thereof.